Pharmacotherapy for the core symptoms of autism spectrum disorder

被引:4
作者
Tan, Peiying [1 ,2 ,3 ]
Shen, Xiaolin [1 ,2 ,3 ]
Zeng, Lizhang [1 ,2 ,3 ]
Weng, Xuchu [1 ,2 ,3 ]
Geng, Hongyan [1 ,2 ,3 ]
机构
[1] South China Normal Univ, Key Lab Brain Cognit & Educ Sci, Minist Educ, Guangzhou 510631, Peoples R China
[2] South China Normal Univ, Inst Brain Res & Rehabil, Guangzhou 510631, Peoples R China
[3] South China Normal Univ, Guangdong Key Lab Mental Hlth & Cognit Sci, Guangzhou 510631, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Autism spectrum disorder (ASD); Core symptom; Pharmacotherapy; Repetitive behaviors; Social dysfunction; BEHAVIORAL SYMPTOMS; INTRANASAL OXYTOCIN; CHILDREN; PREDNISOLONE; ADOLESCENTS; RISPERIDONE; IMPROVES; SYSTEM; TRIAL; RISK;
D O I
10.1631/jzus.B2300864
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Autism spectrum disorder (ASD) is a range of neurodevelopmental diseases characterized by social dysfunction and stereotypic behaviors. The etiology of ASD remains largely unexplored, resulting in a diverse array of described clinical manifestations and varying degrees of severity. Currently, there are no drugs approved by a supervisory organization that can effectively treat the core symptoms of ASD. Childhood and adolescence are crucial stages for making significant achievements in ASD treatment, necessitating the development of drugs specifically for these periods. Based on the drug targets and mechanisms of action, it can be found that atypical psychotropic medications, anti-inflammatory and antioxidant medications, hormonal medications, ion channel medications, and gastrointestinal medications have shown significant improvement in treating the core symptoms of ASD in both children and adolescents. In addition, comparisons of drugs within the same category regarding efficacy and safety have been made to identify better alternatives and promote drug development. While further evaluation of the effectiveness and safety of these medications is needed, they hold great potential for widespread application in the clinical treatment of the principal symptoms of ASD.
引用
收藏
页码:956 / 971
页数:16
相关论文
共 75 条
[21]   Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use [J].
Fleury-Teixeira, Paulo ;
Caixeta, Fabio Viegas ;
Ramires da Silva, Leandro Cruz ;
Brasil-Neto, Joaquim Pereira ;
Malcher-Lopes, Renato .
FRONTIERS IN NEUROLOGY, 2019, 10
[22]   Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial [J].
Frye, R. E. ;
Slattery, J. ;
Delhey, L. ;
Furgerson, B. ;
Strickland, T. ;
Tippett, M. ;
Sailey, A. ;
Wynne, R. ;
Rose, S. ;
Melnyk, S. ;
James, S. Jill ;
Sequeira, J. M. ;
Quadros, E. V. .
MOLECULAR PSYCHIATRY, 2018, 23 (02) :247-256
[23]   Metabolic pathology of autism in relation to redox metabolism [J].
Frye, Richard E. ;
James, S. Jill .
BIOMARKERS IN MEDICINE, 2014, 8 (03) :321-330
[24]   Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study [J].
Hacohen, Micha ;
Stolar, Orit E. ;
Berkovitch, Matitiahu ;
Elkana, Odelia ;
Kohn, Elkana ;
Hazan, Ariela ;
Heyman, Eli ;
Sobol, Yael ;
Waissengreen, Danel ;
Gal, Eynat ;
Dinstein, Ilan .
TRANSLATIONAL PSYCHIATRY, 2022, 12 (01)
[25]   Improving emotional face perception in autism with diuretic bumetanide: A proof-of-concept behavioral and functional brain imaging pilot study [J].
Hadjikhani, Nouchine ;
Zuercher, Nicole R. ;
Rogier, Ophelie ;
Ruest, Torsten ;
Hippolyte, Loyse ;
Ben-Ari, Yehezkel ;
Lemonnier, Eric .
AUTISM, 2015, 19 (02) :149-157
[26]   The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder [J].
Herscu, Paul ;
Handen, Benjamin L. ;
Arnold, L. Eugene ;
Snape, Michael F. ;
Bregman, Joel D. ;
Ginsberg, Lawrence ;
Hendren, Robert ;
Kolevzon, Alexander ;
Melmed, Raun ;
Mintz, Mark ;
Minshew, Nancy ;
Sikich, Linmarie ;
Attalla, Ashraf ;
King, Brian ;
Owley, Thomas ;
Childress, Ann ;
Chugani, Harry ;
Frazier, Jean ;
Cartwright, Charles ;
Murphy, Tanya .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2020, 50 (09) :3233-3244
[27]   New generation antidepressants for depression in children and adolescents: a network meta-analysis [J].
Hetrick, Sarah E. ;
McKenzie, Joanne E. ;
Bailey, Alan P. ;
Sharma, Vartika ;
Moller, Carl, I ;
Badcock, Paul B. ;
Cox, Georgina R. ;
Merry, Sally N. ;
Meader, Nicholas .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (05)
[28]   Autism Spectrum Disorder A Review [J].
Hirota, Tomoya ;
King, Bryan H. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (02) :157-168
[29]   An oral absorbent, AST-120, restores vascular growth and blood flow in ischemic muscles in diabetic mice via modulation of macrophage transition [J].
Huang, Hsin-Lei ;
Kuo, Chin-Sung ;
Chang, Ting-Yung ;
Chou, Ruey-Hsing ;
Chen, I-Chun ;
Yang, Fu-Chen ;
Chen, Nien-Jung ;
Lin, Shing-Jong ;
Wu, Chih-Cheng ;
Huang, Po-Hsun .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2021, 155 :99-110
[30]   Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism [J].
James, S. Jill ;
Melnyk, Stepan ;
Jernigan, Stefanie ;
Cleves, Mario A. ;
Halsted, Charles H. ;
Wong, Donna H. ;
Cutler, Paul ;
Bock, Kenneth ;
Boris, Marvin ;
Bradstreet, J. Jeffrey ;
Baker, Sidney M. ;
Gaylor, David W. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2006, 141B (08) :947-956